Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

ABSTRACT:

Background

Anti-angiogenic therapy with bevacizumab is the most widely used treatment option for recurrent glioblastoma, but therapeutic response varies substantially and effective biomarkers for patient selection are not available. To this end, we determine whether novel quantitative radiomic strategies on the basis of MRI have the potential to noninvasively stratify survival and progression in this patient population.

Methods

In an initial cohort of 126 patients, we identified a distinct set of features representative of the radiographic phenotype on baseline (pretreatment) MRI. These selected features were evaluated on a second cohort of 165 patients from the multicenter BRAIN trial with prospectively acquired clinical and imaging data. Features were evaluated in terms of

SUBMITTER: Grossmann P 

PROVIDER: S-EPMC5716072 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature